ReviewInternational journal of nanomedicine2025
Nanodrug Delivery Systems for Direct Clearance or Neutralization of LPS.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mechanism of Action ofBiology · 2026Article
- Construction, evaluation, and applications of renal barrier-on-a-chip system.Bioactive materials · 2026Review
- Engineered Escherichia coli as a microbial cell factory for intracellular protein delivery: strains, vectors, mechanisms, and therapeutic applications.Microbial cell factories · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipopolysaccharide (LPS) is a unique component of the outer wall of gram-negative bacteria and is a complex composed of lipids and polysaccharides. Normally, liver sinusoidal endothelial cells (LSECs) systemically clear LPS via unknown mechanisms. However, under pathological conditions, LPS causes lethal endotoxemia if it cannot be rapidly cleared from the blood circulation. Currently, an increasing number of drugs have demonstrated the ability to clear or neutralize LPS. However, due to their inherent characteristics, such as low biocompatibility and short half-life, their clinical applications are limited. Nanodrug delivery systems have the advantages of improving pharmacokinetics, increasing bioavailability, reducing the occurrence of side effects, and prolonging drug circulation time, which can compensate for the shortcomings of traditional drugs. This review summarizes nanodrug delivery systems that can clear or neutralize LPS, such as polymer nanodrug delivery systems, lipid-based nanodrug delivery systems, peptide-based nanodrug delivery systems, inorganic nanodrug delivery systems, nanosponges, and extracellular vesicles, which provides an outlook on the application and future prospects of nanodrug delivery systems for clearing and neutralizing LPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.